Antimicrobial wound healing dressings VitaVallis are highly effective solution to the problem of antibiotic resistance of microorganisms for superficial infections. Dressings action is based not on toxic but the physical (Electropositive sorption) action mechanism on the wound and surrounding tissue. Dressing evacuates (absorbs) microorganisms from the wound, immobilizes and inhibits their generation in the dressing. The use of the material does not create resistant strains of bacteria and does not cause allergies and addictions. The material has a clearly defined regenerative effect and is particularly effective in the treatment of wounds that are difficult to treat pharmacologically and by means of other modern dressings.
Competitive advantages :
1. Superior to the best world samples in the effectiveness of antimicrobial and wound healing effect.
2. Reduce treatment period up to 1,5 times.
3. Actively stimulates regenerative tissue.
4. Effective in the treatment of wounds that are difficult to treat pharmacologically.
5. Allow to refuse transplantation of skin with deep and extensive burns.
6. Minimize scarring, reduce pain.
7. Do not have a toxic effect on the wound and surrounding tissue.
8. Do not contain antibiotics and medicines.
9. Do not cause sensitization and allergy during chronic administration.
Application:
Medicine and healthcare, pharmacy and hospital sector.
Assessment of the socio-economic impact :
The use in medical practice of new antiseptic sorption materials and their products for the treatment of wounds of various etiologies reduces the healing time by 1.5-2 times, which increases the capacity of hospitals and reduces the usage of dressings up to 40%. In addition, by reducing the number of dressings work of medical personnel becomes easier. When, a new generation of antimicrobial material is used in medical practice, the economic impact is tens of millions of rubles by reducing the time spent in the hospital.
Potential market :
Market size, mln. USD: 2014 – 5 560, 2015 – 5 870, 2016 – 6 230, 2017 – 6 625, 2018 – 7 075. Minimal need for in modern dressings for the Russian Federation is 70-80 million dressings/year.
A product range :
1. Sorption antimicrobial wound aseptic Dressing for burn wounds treatment, the size: 5cm х 5cm, 10cm х 10cm, 10cm х 20cm.
2. Sorption antimicrobial wound aseptic Dressing for burn wounds treatment, adhesive, the size: 9cm х 5cm, 14cm х 10cm, 15cm х 20cm.
3. Sorption antimicrobial wound aseptic Dressing for long healing wounds treatment, the size: 5cm х 5cm, 10cm х 10cm, 10cm х 20cm.
4. Sorption antimicrobial wound aseptic Dressing for long healing wounds treatment, adhesive, the size: 9cm х 5cm, 14cm х 10cm, 15cm х 20cm.
5. Sorption antimicrobial wound aseptic Dressing for septic wounds treatment, the size: 5cm х 5cm, 10cm х 10cm, 10cm х 20cm.
6. Sorption antimicrobial wound aseptic Dressing for septic wounds treatment, adhesive, the size: 9cm х 5cm, 14cm х 10cm, 15cm х 20cm.
7. Sorption antimicrobial wound aseptic Dressing for post operating wounds, adhesive, the size: 9cm х 5cm, 14cm х 10cm, 15cm х 20cm.
8. Sorption antimicrobial wound aseptic Dressing for skin wounds, the size: 5cm х 5cm, etc.
Current phase :
Pilot batch.
Predicted sales of innovation product:
Sales, mln. USD: 2014 – 1.8, 2015 – 2.9, 2016 – 4.95, 2017 – 8.35, 2018 – 13.4.
Annotation:
The project is aimed at solving global problems – prevention of
strokes in patients with atrial fibrillation. It is projected that by the middle of this century in Russia the number of patients with atrial fibrillation may increase to 7.5-8 million. One of the most reliable
ways to solve the problem is the surgical closing of the left main coronary artery using umbrella-type devices. The aim of the current project is the development of manufacturing umbrella-type devices from NiTi with a modified ion-plasma treated surface layer that will allow import substitution in this group of cardio implants for domestic analogue with improved properties.
Competitive advantages:
1. Higher strength and fatigue properties, which ensure high reliability both during a surgical procedure, and during its operation in a living body.
2. Higher biocompatibility due to the decline of toxic nickel in the surface layer of the implant material, improved corrosion resistance, faster integration of the implant with the body as a result of purposeful influence on the proliferation of cells in the body.
3. Lower price (no more than $ US1500).
Application:
Products of the project are a domestic analogue of cardio implants designed for the effective prevention of strokes in patients with atrial fibrillation by surgical closing the left main coronary artery. Features of the economy sector to launch the product/technology. The introduction of national umbrella-type devices with improved properties – is a significant contribution to the advancement of “Medical technology and pharmaceuticals,” an important step towards the country’s independence from import agents for the prevention of strokes. It is an important economic effect.
Assessment of the socio-economic impact:
Stroke on atrial fibrillation is more severe, with an increased risk of death (20%) and disability (60%) of patients. The use of umbrella-type devices for the treatment of this disease reduces the risk of
death from cardioembolic strokes, reduces the social costs and the costs of health care by decreasing the number of disabled patients, stops lifetime costs patients on anticoagulation therapy and its
control.
Potential market:
Market: cardio implants, market segment: of left main coronary artery occluders.
Market size: up to 75 000 surgeries.
Russian market share in 2018: about 5%.
Targeted consumers: medical institutions of cardiovascular surgery.
A product range:
Cardio implants – umbrella-type devices (occluders) with modified surface layer (5 standard sizes).
Current phase:
Pilot production.
Time to market:
The supposed time to market is 2014.
Predicted sales of innovation product:
Sales, mln. rubles/year: 2014 – 20, 2015 – 40, 2016 – 160, 2017 – 320, 2018 – 360. By 2018 it is planned to take up 10% of the Russian market of the left main coronary artery occluders, surpassing import devices due to cost leadership. In the future, annual sales will increase by 15-20%.
Annotation:
Ceramic having skeletal structure with the specified distribution of pore elements that have a strictly defined size was developed. The resulting porous zirconia ceramics made from nanocrystalline
powder is not only elastically comparable with the bone, but its structure is similar to the structure of the porous bone tissue, which results in a maximum similarity in their mechanical
behavior. Analysis of the fracture surface of the resulting ceramic showed that the ceramic framework is formed from linear chain of grains with a high bonding strength at the borders and make it
highly resistant to external mechanical influences. The fundamental structural and physic-chemical mechanisms of bone tissue destruction at high-speed shock wounding effects were established. A common in failure mechanisms of different types of bone tissue is a transformation of the porous bone matrix, amorphization of hydroxyapatite.
Competitive advantages:
Biological properties of ceramic materials for creating implants currently are the most actively studied, and also the basic scientific and clinical subjects of interest are the types of skeletal implants
based on ceramics with the defined characteristics of «through porosity. “Through porosity” of the element that is in contact with the bone is one of the main factors to reproduce the capillary effect, which provides tissue ingrowth into the pore, and to use the internal pore space as a “depot-form” to put there the factors of living and nonliving nature . Besides the need of through porosity, the fact of the influence of implant external pores on the speed and volume of ingrowing bone should be taken into account. The authors developed ceramics having a skeletal structure with the specified gradient distribution of pore elements that have a strictly defined size. The resulting porous zirconia ceramics made from nanocrystalline powder is not only elastically comparable with the bone, but its structure is similar to the structure of the porous bone tissue, which results in a maximum similarity in their mechanical behavior. There are no analogues.
Application:
Within the realization of the project it is planned to create a
technology and produce the following product range:
1. Implants for lower-cervical spine.
2. Hip implants.
3. Knee implants.
4. Elbow implants.
5. Implants of chest and lumbar parts spine.
6. Shoulder implant.
7. Foot and finger implants.
Assessment of the socio-economic impact:
The project will develop high-quality ceramic implants, implantable components and systems for Traumatology and Orthopedics of national manufacturing and establish their mass production. As a
result of the successful implementation of this project the volume of domestic exports of medical products in the CIS countries, Asia and the Middle East will be increased.
Potential market:
Share of import implants, mln. USD: 2009 – 43.76, 2010 – 55.63, 2011 – 66.79.
A product range:
1. Implants for lower-cervical spine.
2. Hip implants.
3. Knee implants.
4. Elbow implants.
5. Implants of chest and lumbar parts spine.
6. Shoulder implant.
7. Foot and finger implants.
Current phase:
Pilot production.
Time to market:
The supposed time to market is 2014.
Predicted sales of innovation product:
Sales, mln. rubles: 2014 – 8.4, 2015 – 34.2, 2016 – 326.3, 2017 – 357.3.
Annotation:
During the implementation of the project with the help of nanotechnology electron beam synthesis innovative original hepatoprotective agent – an immobilized hyaluronate-endo-β-N-atsetilgeksozaminidaza was created. Up to the present moment, the technology of its production, including the technology of raw materials, synthesis and purification of substances, production of
dosage form was developed. Preclinical studies of specific hepatoprotective activity of a medicine are conducted: on a model of chronic toxic hepatitis caused by injection of carbon tetrachloride, and on the model of viral hepatitis, simulated by the injection of the D-galactosamine. In order to develop optimal therapeutic regimens action modes of the medicine are studied in detail, including its effect on the proliferative differentiation status of the liver stem cells and precursor cells of depot tissues, and explores the migration processes of stem cells when injected with hyaluronate-endo-β-N-atsetilgeksozaminidaza. In the experiment on different types of animals acute and chronic toxicity, immunotoxicity, reproductive toxicity and mutagenicity of the immobilized hyaluronate-endo-β-N-atsetilgeksozaminidazy are identified.
Competitive advantage:
In the global pharmaceutical market, there are no hepatoprotective medicines with a similar mode of action; the development of analogues in the world literature is not described. The action of the
existing hepatics is based on cytoprotective properties and is not related to the stimulation of regenerative processes.
Application:
Gastroenterology.
Features of the economy sector to launch the product/technology:
Biopharmaceutical sector of the economy as a whole is developing very dynamically. In recent years, Russia has built a number of biotech lines equipped with modern appliances; a lot of attention is paid to the development of nanotechnology, which gives hope for prospects. However, the observed development is carried out through the development and production of biosimilars, with the lack of original biotechnological means.
Assessment of the socio-economic impact:
Therapy with the developed immobilized hyaluronate-endo-β-N-atsetilgeksozaminidazy will have a good therapeutic effect for 6 months, up to the full treatment of patients with chronic hepatitis
of not infectious nature that seems impossible today. In addition, the medicine will be included into a complex treatment of infectious, viral hepatitis, which are one of the most socially significant diseases. In this case, the inclusion of the medicine into the treatment regimen will not only prevent the development of cirrhosis and liver cancer, but also cause regression of cirrhotic organ damage.
.
Potential market:
Sales of medicines for the treatment of specified diseases in Russia make up more than 20 billion rubles in a year.
A product range:
Immobilized hyaluronate-endo-β-N-atsetilgeksozaminidazy.
Current phase:
Pilot production.
Time to market :
The supposed time to market is 2014-2015.
Predicted sales of innovation product:
Prediction sales of the developed medicine in Russia and State Procurement for 10 years from the time-to-market are 200 million rubles.
Annotation:
Alzheimer’s disease (AD) is the most common form of dementia in the elderly, which is characterized by a steady decline in cognitive function and memory until the complete disintegration of the
personality. The task of prevention and treatment of AD can be achieved by launching innovative medicine based on diazobitsiklononan derivative OSPL-502 into a new domestic market. The basis for this statement is previous studies of the physiological activity of the compound OSPL-502, which showed its unique cognitive-stimulating and neuroprotective properties. In the course of the project in-depth testing of specific nootropic activity of OSPL-502 as a cognitive stimulant and neuroprotective agent in animals with progeartric models and the study of the compound OSPL-502mode of action and its receptor profile are carried out. The studies pharmacokinetics of OSPL-502 are conducted. Toxicological testing of OSPL-502 and dosage form based on it is
also conducted, in particular, the study of the common acute and chronic toxicity, immunotoxicity study, mutagenicity, reproductive toxicity, allergenicity, in accordance with the standards of “good
laboratory practice”. For this purpose, capacities of the recently opened IPAC RAS Center of preclinical studies, providing pre-clinical trials in accordance with the requirements of “GLP” are
used. Carrying out the above studies will explore in depth the specific nootropic activity and mode of action of the compound OSPL-502 and dosage form based on it, determine the toxicity and possible side effects. In the case of positive pre-clinical studies a medicine candidate based on OSPL-502 will be submitted for clinical trials.
Competitive advantage:
Potential medicine based on OSPL-502 is effective at very low doses (0.1 -0.2 mg / kg), non-toxic (Hazard Class 4), has the original structure and mode of action.
Application:
Medicine and pharmacy.
Potential market:
The segment of medicines for the treatment of AD in Europe and the United States is the fastest growing, if the average increase in sales of medicines in 2010 compared to 2009 increased by 10%, the
increase in sales of medicines for the treatment of AD during the same period increased by 20% and amounted to $ 8.3 billion, i.e. about 9.5% of the market. The Russian pharmaceutical market in 2010 amounted to 395, 531 billion rubles. The share of neuro-and psychotropic medicines accounted for 21, 5 billion rubles. The growth of this segment of the market in 2010 compared to 2009 was about 9.8%.
A product range:
A medicine for the treatment of Alzheimer’s and other neurodegenerative diseases, the main feature of which is impairment of memory and cognitive functions.
Current phase:
Pre-clinical studies of a medicine.
Time to market :
The supposed time to market is 2018.
Predicted sales of innovation product:
Sales, mln. rubles a year: 2019 – 100, 2020 – 300, 2021 – 600.
Annotation:
New hi-tech production facilities to manufacture important semiproducts (glycolic acid, glycolide and lactide mononers, poly(glycolide-co-lactide) polymers) and desired product (synthetic
biologically inert monofilament suture) have been established. The implementation of the innovative project will not only get a Russian-quality synthetic surgical thread of a lower price, but
create a scalable technology to produce Russian synthetic bioresorbable medical polymer materials and products, create a backlog for the development of technologies to produce biocompatible biodegradable polymer materials and products, approved and available for use by the Russian medical institutions, and used for tissue repair and functions of the human body in
injuries of different etymology, as well as the reconstruction of bone tissue and organs. The economic impact should be achieved by the introduction of biodegradable medical materials and products on the world market in the field of veterinary and medicine.
Competitive advantage:
New hi-tech production facilities to manufacture important semiproducts (glycolic acid, glycolide and lactide mononers, poly (glycolide-co-lactide) polymers and desired product (synthetic
biologically inert monofilament suture) have been established. The developed equipment and technology allow reducing the losses of expensive raw materials and improving the purity of the semi-products and the product itself.
Application:
Medicine, chemical industry.
Features of the economy sector to launch the product/technology:
The Russian market of biodegradable surgical sutures depends on the importing. Since there are no Russian producers of up-to-date surgical suture, the demand in sutures made of PGLA copolymers
is supplied by the sutures of foreign manufacture.
Assessment of the socio-economic impact:
Every year the number of the operations in Russia increases by an average 1.7%, which leads to an increase in the need for sutures.
A product range:
65% Glycolic acid, glycolide, lactide, copolymers of glycolic and lactic acid, monofilament surgical sutures from a copolymer PGLA. Implementation of the project will lead to the creation of new
production, the products of which will contribute significantly to the quality of vital surgery of the various organs and tissues reduce the number of complications related to the use of medical
materials. Developed medical supplies will in the long run solve an important social task of providing the citizens of the Russian Federation with necessary medical care, refuse similar import
products.
Potential market :
General data on the volume of imports are: in 2011 Russia imported 107.7 tons of surgical sutures for a total of 34,945 thousand USD. In in the first half of 2012, imports amounted to
45.2 tons (15.2 million USD). It should be noted that in the structure of Russian imports a large part of the supplies accounts for gut – about 15% of total shipments in 2011 (or 16.5 tons). This fact is especially remarkable in light of the prohibition on the use of catgut in a number of European countries. It is expected that, in value terms, the total market size of suture materials in Russia in 2018 will increase by more than half and reach 13.2 billion rubles, even in a conservative forecast, and in view of the reforms and the ongoing government programs – with a growth rate of 15 -20% per year, by 2018 the market will increase the by 3-4 times and will exceed 30 billion rubles.
Current phase:
The pilot batch.
Time to market :
The supposed time to market is 2014-2015.
Predicted sales of innovation product:
Sales, mln. rubles a year: 2014 – 45, 2015 – 90.
Annotation:
In medicine, the data on the genome uniquely identify infectious agents (viruses, bacteria, parasites), clarify their biological characteristics (degree of pathogenicity) and determine treatment
and prevention (for example, the sensitivity to certain drugs). Automated devices for reading the sequence of nucleotides in DNA (DNA sequencing) and the analysis of their individual fragments are
called genetic analyzers (sequencers). In genetic analyzer method for separating nucleic acid molecules in the liquid polymeric phase simultaneously in 8 capillaries under high voltage with five color laser-induced fluorescence detection is used. The following materials and reagent kits were specially designed for genetic analyzer: polymer for separation of DNA fragments; spectral
calibrator for fragment analysis, spectral calibrator for sequencing DNA, and molecular weight marker.
Competitive advantage:
The analyzer characteristics and productivity are competitive with the top analogs. The preliminary cost of the genetic analyzer is not more than 1.5 million rubles for sale in the territory of Russia, and
not more than 2 million rubles for supplies to foreign markets, with the cost of foreign analogues from 5 to 20 million rubles. The cost of consumables is 3-4 times less than of foreign analogues.
Proprietary design of reagent kits allows analyzing DNA fragments up to 700 nucleotides for the price 4 times lower compared with the analogs (from 600 to 150 rubles accordingly). A wide range of
biomedical research methods are accommodated to the instrument.
Application:
The analyzer can be used for sequencing and fragment analysis of DNA samples obtained from biological materials in clinical studies, medical genetics, bio-safety and security control, ecology and
forensic applications.
Features of the economy sector to launch the product/technology:
The genetic analyzer is used for sequencing and fragment analysis of DNA to meet the needs of medicine and biomedical research.
Assessment of the socio-economic impact:
One of the commercial applications of genetic analyzer is to get the results of the genetic survey of people from childhood (“genetic passport”), containing information on the probability of developing genetic diseases and characteristics of the organism to predict individual responses to medicines.
Potential market:
Consumers of the genetic analyzer will basically be numerous public institutions: health clinics, hospitals, laboratories, research institutes, high schools, universities, institutional structures, such
as Ministry of Internal Affairs, the FSB, the forensic laboratories of the Health Ministry, Ministry of Defense, Ministry of Agriculture of the Russian Federation testing laboratories and Russian Ministry of
Education R & D laboratories.
A product range:
Genetic analyzer, sample preparation devices, materials and kits of reagents: polymer for separation of DNA fragments; spectral Calibrators for fragment analysis and sequencing of the DNA,
molecular weight marker.
Current phase:
Pilot prototype.
Time-to-market:
2014
Predicted sales of innovation product:
Annual sales result (units): 2015 – 50; 2016 – 60; 2017 – 70; 2018 – 80.
Annotation::
The aim of the technological works is the development of resource-saving technologies and production equipment for the catalytic synthesis of 2-methylimidazole. Due to its electron-unsaturated structure 2-methylimidazole has high reaction capacity. This property allows using it as raw material in the manufacture of pharmaceuticals, agricultural chemicals, auxiliary lubricants, powder paints, etc. The main consumers of 2-methylimidazole are company-producers of active pharmaceutical ingredients, using it as a feedstock to produce anti-infective substances: metronidazole, ornidazole, tinidazole, ketoconazole, dimetridazole, clotrimazole, fluconazole, etc. Some of them are included in the list of vital and essential medicines approved by the Decree of the Russian Federation Government dated December 30, 2009 № 2135-r, such as metronidazole. In this respect, the development of original technology of 2-methylimidazole production and the creation of pilot production is an urgent task.
Competitive advantage:
Reduced cost of raw materials and products.
Application:
Raw material for production of pharmaceutical substances.
Assessment of the socio-economic impact:
Plants for the production of 2-methylimidazole exist in Germany (the company BASF, up to 3,000 tons / year), Japan (Concern The Nippon Synthetic Chemical Industry Co., Ltd. 2,000 tons / year).
Total world production and consumption of 2-methylimidazole is not less than 10,000 tons per year (1.5 billion U.S. dollars). The average annual consumption of 2-methylimidazole in Russia is estimated at 750 tons (600 million rubles). At present, Russian manufacturers of pharmaceutical substances on the basis of 2-methylimidazole (JSC “Dalfarm”, JSC “Nizhpharm”, LLC “Pharmstandard”, LLC “Kamelotfarm”, LLC “LEKPHARM”, etc.) are using imported raw materials of Chinese (500,000 rubles. / ton) and German (1000000 rub. / ton) production, which determines
the high cost of finished dosage forms. The cost of the national 2-methylimidazole is estimated at 220 000 rub. / ton. Produced 2-methylimidazole is planned to use for the production of active
pharmaceutical substances-generics by own technologies.
Potential market:
Russia, CIS countries.
A product range:
2-methylimidazole.
Current phase:
Pilot prototype.
Time-to-market :
2014
Predicted sales of innovation product:
Predicted sales are 100 tons/year.
Annotation:
The project aims to develop technology for specific antigens and DNA of Opisthorchosis based on genome-sequencing Structural and functional annotation of genes of Opisthorchosis was carried out. The annotated genome was used to identify target genes that serve as species-specific markers, develop kits for specific DNA diagnostics of Opisthorchosis, as well as to produce recombinant antigens for enzyme immunosorbent diagnostics – the development of reagents for the detection of antibodies to Opistorchis fellineus.
Competitive advantage :
Reagent Kit «InVitroLogic Opisthorchosis AT” – is designed for the determination of total immunosorbent antibody to Opistorchis fellineus in serum or plasma.
The advantages of the kit:
1. Specificity on an array of negative samples – not less than 98%.
2. Sensitivity on the array of samples confirmed by koproovoskopiya – not less than 97%.
3. All the components included into the kit, painted in different colors for easy visual control when working with them.
4. Signal light entering the sample on the tablet allows avoiding mistakes at this stage of the analysis. Conjugate and chromogen solutions do not require dilution. This reduces the number of operations in setting of analysis, makes a kit more convenient and safe to use.
5. Each reagent kit is accompanied with additional supplies needed for the IFA: bath, tips, and adhesive tape for the incubation of a tablet.
Reagent kit «InVitroLogic DNA opisthorchis” – for detection of DNA of four kinds of pathogens in samples of human feces based on polymerase chain reaction with the detection of a fluorescent signal in real time (real time PCR). The advantages of the kit: can detect DNA O.felineus, C.sinensis, O.viverrini, M.bilis and their mixed-infestation in a single cycle analysis; provides high specificity and sensitivity of the analysis; automates the process of diagnosis; compatible with a thermal cycler CFX96 (BioRad), RotorGene 6000 (Quiagen), DTlite (DNA Technology).
Application:
Clinical Laboratory Diagnostics.
Features of the economy sector to launch the product/technology:
Laboratory medicine.
Assessment of the socio-economic impact:
Improving the efficiency of early Opisthorchosis diagnosis is crucial for effective therapy, reduction the risk of severe liver disease, increasing quality of life and health of the population in endemic regions.
Potential market:
The needs of the Russian market in endemic regions of the Siberian Federal District make up at least 3 million tests per year. A potential market of the Russian Federation, Ukraine, Kazakhstan
exceeds 200 million rubles. Also, products are competitive on the international market in South-East Asia.
A product range:
1. Reagent Kit «InVitroLogic DNA opisthorchis”.
2. Reagent Kit «InVitroLogic opisthorchis AT”.
Current phase:
Pilot prototype.
Time-to-market:
2013
Predicted sales of innovation product:
Predicted sales mln. rubles/year: 2013 – 50; 2014 – 90.
Annotation:
Development of a gas analyzer that operates on the basis of laser opto-acoustic spectroscopy with the possibility of registering at least 10 volatile compounds in exhaled air at low cost of the study.
Competitive advantage The number of registered substances during the analysis of one sample. The concentration sensitivity.
Application:
Medicine and health care, physics, chemistry, biotechnology,
environmental protection, human ecology.
Features of the economy sector to launch the product/technology:
Private healthcare sector for the market of analyzers is present, but to work effectively it will need to develop clear business models based on the use of the developed device.
Assessment of the socio-economic impact:
The proposed technical method for the registration of exhaled air by the opto-acoustic spectroscopy based on an optical parametric oscillator with opto-acoustic detector will significantly reduce the cost of manufacture of devices for the diagnosis of the bronchi and lungs diseases, compared with foreign analogues.
Potential market:
Hospitals, ambulatory clinics, research organizations in Russia and abroad.
A product range:
Laser optical-acoustic multi-gas analyzer Laser Breeze for medical diagnosis.
Current phase:
Pilot prototype production.
Time-to-market :
2014
Predicted sales of innovation product:
Sales: 50 units a year.
Annotation:
The aim is to develop a technology of mass spectrometric marker peptides screening necessary for the quantitative determination of human proteome, and application of the established marker
peptides for the identification of encoded by the 18th chromosome genes in the proteins biomaterial.
Competitive advantage:
Created by the technology of measuring the concentration of proteins in samples of biological material by mass spectrometry is used for the analysis of proteins in different organs and tissues of
humans to find new biomarkers, diagnostic methods and treatment of diseases. The technology is applicable for measuring the concentration of proteins important for modern molecular medicine
and biotechnology. Obtained according to the developed technology signatures allow the quantitative analysis of proteins with absolute (100%) sensitivity and specificity up to 10-15 mole / l, which is three times superior to the existing methods based on IFA.
Application:
Molecule medicine and biotechnology Features of the economy sector to launch the product/technology Products are prepared for entering the market of antibodies, the amount of which, according to experts, will be 2,449 billion rubles by 2015.
Assessment of the socio-economic impact:
Implementation of the project will start biomedical research first in the experimental laboratory practice, and then – in the clinical diagnostic laboratories a number of standard tests, including
immunohistochemistry, Western blotting, protein microarrays, and enzyme-linked immunosorbent analysis. In the study of well-characterized protein (less than 1% of all human proteins), duly
registered as a biomarker of disease provided mass-production of antibodies to it, the cost of the analysis with the use of the developed reagents kit will be reduced by 2-3 times. In the study of less-studied proteins, which include 99% of the genome, the savings will be up to 10-50 times, due to the absence in the cost of new product development, testing and production of antibodies
expenses.
Potential market:
Scientific and research organizations, clinical and diagnostic laboratories.
A product range:
A kit of marker peptides (Cat. № IBMC0078) The state standard sample of marker peptides (SSS 10155-2012).
Current phase:
Pilot production with working off the cycle of the process.
Time-to-market:
2014
Predicted sales of innovation product:
At the initial stage the sales will be oriented to the foreign market, the volume of which in 2014 is projected 100 -300 thousand dollars. The second area of commercialization of a comparable size
of the market is selling kits complete with mass spectrometry equipment. The third area of commercialization is planned in the form of orders for the manufacture of original sets, as well as for
the execution of complex orders, including manufacturing.
